DUBLIN – The U.S. Food and Drug Administration has expanded approval of Medtronic’s MiniMed 670G system for patients with Type 1 diabetes age seven and older. The system was previously approved for those age 14 and older. “We are thrilled to be able to offer this advanced insulin management system to younger patients and their caregivers to help alleviate some of the burden associated with this unrelenting disease and to improve their quality of life,” said Dr. Francine Kaufman, chief medical officer and vice president of global regulatory, medical and clinical affairs of the Diabetes Group at Medtronic, in a statement. “This expanded age indication provides an important new treatment option for pediatric clinicians and parents of young children with Type 1 diabetes, and further demonstrates our strong commitment to improving outcomes across the full diabetes care continuum.” The MiniMed system features the company’s SmartGuard technology and Guardian Sensor 3 continuous glucose monitoring, which work together to automate the delivery of a personalized amount of basal insulin every five minutes based on sensor glucose values. The system constantly self-adjusts to help avoid highs and lows.
You are here: / / MiniMed diabetes management system approved for pediatric use